このページの翻訳は実験的なもので、現在開発中です。お待ちしております！
GBT 株式概要
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD).
Global Blood Therapeutics, Inc. 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$68.49 |
| 52週高値 | US$73.02 |
| 52週安値 | US$21.65 |
| ベータ | 0.46 |
| 11ヶ月の変化 | 1.02% |
| 3ヶ月変化 | 98.98% |
| 1年変化 | 169.54% |
| 33年間の変化 | 45.26% |
| 5年間の変化 | 106.30% |
| IPOからの変化 | 58.87% |
最新ニュース
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Health Check: How Prudently Does Global Blood Therapeutics (NASDAQ:GBT) Use Debt?
Dec 03株主還元
| GBT | US Biotechs | US 市場 | |
|---|---|---|---|
| 7D | 0.6% | -1.3% | 0.4% |
| 1Y | 169.5% | 7.7% | 22.9% |
業界別リターン: GBT過去 1 年間で8.4 % の収益を上げたUS Biotechs業界を上回りました。
リターン対市場: GBT過去 1 年間で21.8 % の収益を上げたUS市場を上回りました。
価格変動
| GBT volatility | |
|---|---|
| GBT Average Weekly Movement | 15.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
安定した株価: GBTの株価は過去 3 か月間にわたって変動しています。
時間の経過による変動: GBTの weekly volatility ( 15% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 2011 | 457 | Ted Love | www.gbt.com |
Global Blood Therapeutics, Inc. 基礎のまとめ
| GBT 基礎統計学 | |
|---|---|
| 時価総額 | US$4.62b |
| 収益（TTM） | -US$322.46m |
| 売上高(TTM) | US$234.86m |
19.7x
P/Sレシオ-14.3x
PER（株価収益率GBT は割高か？
公正価値と評価分析を参照収益と収入
| GBT 損益計算書（TTM） | |
|---|---|
| 収益 | US$234.86m |
| 売上原価 | US$4.45m |
| 売上総利益 | US$230.41m |
| その他の費用 | US$552.87m |
| 収益 | -US$322.46m |
直近の収益報告
Jun 30, 2022
次回決算日
該当なし
| 一株当たり利益（EPS） | -4.78 |
| グロス・マージン | 98.10% |
| 純利益率 | -137.30% |
| 有利子負債／自己資本比率 | 491.7% |
GBT の長期的なパフォーマンスは？
過去の実績と比較を見る